186 related articles for article (PubMed ID: 31046644)
1. Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand- and structure-based approaches.
Cutinho PF; Roy J; Anand A; Cheluvaraj R; Murahari M; Chimatapu HSV
J Biomol Struct Dyn; 2020 Apr; 38(6):1626-1648. PubMed ID: 31046644
[TBL] [Abstract][Full Text] [Related]
2. Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II).
Cutinho PF; Shankar RC; Anand A; Roy J; Mehta CH; Nayak UY; Murahari M
J Biomol Struct Dyn; 2020 Aug; 38(13):3772-3789. PubMed ID: 31526232
[TBL] [Abstract][Full Text] [Related]
3. A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.
Panigrahi D; Mishra A; Sahu SK; Azam MA; Vyshaag CM
Med Chem; 2022; 18(1):51-87. PubMed ID: 33319692
[TBL] [Abstract][Full Text] [Related]
4. An
da Costa APL; Cardoso FJB; Molfetta FA
J Biomol Struct Dyn; 2023 Mar; 41(5):1715-1729. PubMed ID: 34996334
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV potential of diarylpyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors: design, synthesis, docking, TOPKAT analysis and molecular dynamics simulations.
Singh VK; Srivastava R; Gupta PSS; Naaz F; Chaurasia H; Mishra R; Rana MK; Singh RK
J Biomol Struct Dyn; 2021 Apr; 39(7):2430-2446. PubMed ID: 32216610
[TBL] [Abstract][Full Text] [Related]
6. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission.
D'Cruz OJ; Uckun FM
Curr HIV Res; 2006 Jul; 4(3):329-45. PubMed ID: 16842085
[TBL] [Abstract][Full Text] [Related]
7. New strategy for identifying potential natural HIV-1 non-nucleoside reverse transcriptase inhibitors against drug-resistance: an
Wang Y; Wang X; Xiong Y; Kaushik AC; Muhammad J; Khan A; Dai H; Wei DQ
J Biomol Struct Dyn; 2020 Jul; 38(11):3327-3341. PubMed ID: 31422767
[TBL] [Abstract][Full Text] [Related]
8. Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents.
Cele FN; Ramesh M; Soliman ME
Drug Des Devel Ther; 2016; 10():1365-77. PubMed ID: 27114700
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibitor design for HIV-1 reverse transcriptase and integrase enzymes: a molecular docking study.
Ercan S; Şenyiğit B; Şenses Y
J Biomol Struct Dyn; 2020 Feb; 38(2):573-580. PubMed ID: 31787027
[TBL] [Abstract][Full Text] [Related]
10. Chemical structure and correlation analysis of HIV-1 NNRT and NRT inhibitors and database-curated, published inhibition constants with chemical structure in diverse datasets.
Viira B; García-Sosa AT; Maran U
J Mol Graph Model; 2017 Sep; 76():205-223. PubMed ID: 28738270
[TBL] [Abstract][Full Text] [Related]
11. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
12. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
Xu H
Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV.
Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
J Biomol Struct Dyn; 2019 Jan; 37(1):131-146. PubMed ID: 29268664
[TBL] [Abstract][Full Text] [Related]
14. Revolutionizing antiretroviral therapy for human immunodeficiency virus/AIDS: A computational approach using molecular docking, virtual screening, and 3D pharmacophore building to address therapeutic failure and propose highly effective candidates.
Annan A; Raiss N; Elmir EH; Filali-Maltouf A; Medraoui L; Oumzil H
Int J Immunopathol Pharmacol; 2023; 37():3946320231207514. PubMed ID: 37850462
[TBL] [Abstract][Full Text] [Related]
15. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.
D'Cruz OJ; Uckun FM
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):329-50. PubMed ID: 17059165
[TBL] [Abstract][Full Text] [Related]
16. In silico design, synthesis and anti-HIV activity of quinoline derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Singh VK; Mishra R; Kumari P; Som A; Yadav AK; Ram NK; Kumar P; Schols D; Singh RK
Comput Biol Chem; 2022 Jun; 98():107675. PubMed ID: 35395595
[TBL] [Abstract][Full Text] [Related]
17. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Liu G; Wan Y; Wang W; Fang S; Gu S; Ju X
Mol Divers; 2019 Feb; 23(1):107-121. PubMed ID: 30051344
[TBL] [Abstract][Full Text] [Related]
18. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
Liu G; Wang W; Wan Y; Ju X; Gu S
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
[TBL] [Abstract][Full Text] [Related]
19. Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H.
Wang L; Sarafianos SG; Wang Z
Acc Chem Res; 2020 Jan; 53(1):218-230. PubMed ID: 31880912
[TBL] [Abstract][Full Text] [Related]
20. ANN QSAR workflow for predicting the inhibition of HIV-1 reverse transcriptase by pyridinone non-nucleoside derivatives.
Barzegar A; Zamani-Gharehchamani E; Kadkhodaie-Ilkhchi A
Future Med Chem; 2017 Jul; 9(11):1175-1191. PubMed ID: 28722475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
